Navigating key news stories in pharma

Lonza Banner
Codis
SCHOTT Banner

Featured Stories

Featured
Rewriting the Outsourcing Playbook
Future Biopharma
Rewriting the Outsourcing Playbook
Future Biopharma

Macroeconomic headwinds, compressed regulatory pathways, and an influx of asset-light virtual innovators are leading to an evolution in outsourcing service delivery models.

Read more →
Future Biopharma
News
Rewriting the Outsourcing Playbook
Future Biopharma
Rewriting the Outsourcing Playbook
Future Biopharma

Macroeconomic headwinds, compressed regulatory pathways, and an influx of asset-light virtual innovators are leading to an evolution in outsourcing service delivery models.

Read more →
Future Biopharma
Ethyreal Bio Launches to Advance Dual-Targeting Thyroid Therapy
Strategy
Ethyreal Bio Launches to Advance Dual-Targeting Thyroid Therapy
Strategy

Backed by USD 101 million in cumulative financing, Ethyreal Bio is targeting the shared pathogenic driver of Graves' disease and thyroid eye disease with a differentiated, long-acting subcutaneous antibody.

Read more →
Strategy
AI-Designed Universal Coronavirus Vaccine Passes First Human Trial
Future Biopharma
AI-Designed Universal Coronavirus Vaccine Passes First Human Trial
Future Biopharma

A novel pan-sarbecovirus vaccine candidate developed by the University of Cambridge and DIOSynVax has demonstrated safety in a Phase I, needle-free clinical trial.

Read more →
Future Biopharma

R&D

Featured
AbbVie Targets Obesity Market with Novel Drug
AbbVie Targets Obesity Market with Novel Drug

Phase I trial results for the company’s novel long-acting amylin analog, have demonstrated significant potential for patients to lose up to 9.79% of body weight in 12–13 weeks with no serious adverse events.

NOFLU Consortium Awarded Contract Worth Up to EUR 148 Million
NOFLU Consortium Awarded Contract Worth Up to EUR 148 Million

The funding, which is part of a larger investment commitment from the European Commission, will be used to progress Ethris’ differentiated mRNA vaccine technology as a treatment for pandemic flu.

Preclinical Study Finds Nanotrastuzumab to be Comparable with Herceptin HYLECTA
Preclinical Study Finds Nanotrastuzumab to be Comparable with Herceptin HYLECTA

The nanoparticle suspension formulation was found to mirror the reference product closely in terms of AUC, Cmax, and Tmax across a 21-day Göttingen minipig study performed by Charles River Laboratories.

Novo Nordisk Reveals Headline Phase III Trial Results Evaluating Combination Obesity Treatment
Novo Nordisk Reveals Headline Phase III Trial Results Evaluating Combination Obesity Treatment

The company’s fixed-dose combination treatment demonstrated superior efficacy to its individual components and was shown to be safe and well-tolerated, consisted with other incretin and amylin-based therapies.

Expansion

Featured
Curia Enhances Sterile Manufacturing Integrity with Upgraded Aseptic Suites
Curia Enhances Sterile Manufacturing Integrity with Upgraded Aseptic Suites

Ahead of its exhibition at CPHI Americas, Curia announced the completion of its Spanish aseptic upgrades alongside concurrent sterile vial filling and lyophilization expansions underway in Glasgow.

Intertek Scales Capacity for Complex Drug Stability Testing
Intertek Scales Capacity for Complex Drug Stability Testing

The company’s expanded stability storage hub now delivers a wide spectrum of ICH-compliant and ultra-low-temperature solutions, addressing growing needs for stability data and GMP analytical support across complex drug programs.

PCI Pharma Services Unveils Major Expansion
PCI Pharma Services Unveils Major Expansion

Philadelphia-based CDMO, PCI Pharma Services, has committed to substantial investments in sterile fill/finish and drug-device combination assembly across its global operations.

A Modular Revolution in Biomanufacturing
A Modular Revolution in Biomanufacturing

SPONSORED CONTENT: As CDMOs face increasing demand for agility and resilience, Azam Razzaq from FUJIFILM Biotechnologies reveals how the expanded Borealis facility is helping to bridge the gap between clinical supply and commercial reality for sponsors.

Dealmaking

Featured
Circio Expands circVec Platform with GenAssist Collaboration
Circio Expands circVec Platform with GenAssist Collaboration

The objective of the joint research collaboration between Circio and GenAssist is to evaluate potential synergy between the companies’ complementary technologies for the development of next-gen AAVs.

Ascidian Partners with Eli Lilly on RNA Editing for Monogenic Kidney Targets
Ascidian Partners with Eli Lilly on RNA Editing for Monogenic Kidney Targets

A newly signed USD 1.9 billion global research collaboration and licensing agreement is set to combine Ascidian Therapeutics’ exon editing platform with Eli Lilly’s expertise in genetic medicines.

Lilly Agrees to Buy Three Vaccine Developers in Infectious Disease Deal
Lilly Agrees to Buy Three Vaccine Developers in Infectious Disease Deal

The acquisitions of Curevo, LimmaTech Biologics, and Vaccine Company will enable the pharma giant to build a pipeline targeting viral and bacterial pathogens linked to long-term neurological and oncological risks.

GSK Partners with CTTQ to Fast-Track Bepirovirsen Launch in China
GSK Partners with CTTQ to Fast-Track Bepirovirsen Launch in China

An exclusive, strategic deal between GSK and Sino Biopharmaceutical's CTTQ unit in China has been struck with the aim of accelerating the rollout of bepirovirsen for Chinese patients.

Strategy

Featured
Ethyreal Bio Launches to Advance Dual-Targeting Thyroid Therapy
Ethyreal Bio Launches to Advance Dual-Targeting Thyroid Therapy

Backed by USD 101 million in cumulative financing, Ethyreal Bio is targeting the shared pathogenic driver of Graves' disease and thyroid eye disease with a differentiated, long-acting subcutaneous antibody.

CPHI Americas 2026: A Platform for Strategic Conversation
CPHI Americas 2026: A Platform for Strategic Conversation

As the pharmaceutical supply chain digitizes, the unique human element of face-to-face networking remains fundamental, according to Sherma Ellis-Daal, Brand Director for CPHI Americas.

CPHI Americas 2026: Anchoring the Pipeline
CPHI Americas 2026: Anchoring the Pipeline

Ahead of CPHI Americas, Kent Payne from Wilmington PharmaTech reveals how shifting geopolitical regulations, private equity capital, and specialized technical expertise are driving domestic pharmaceutical manufacturing.

Modernizing Generic and Biosimilar Formulation
Modernizing Generic and Biosimilar Formulation

As the generic and biosimilar market enters a period of growth, developers are moving away from costly empirical testing and leveraging advanced technologies to overcome technical hurdles to formulation.

Future Biopharma

Featured
Rewriting the Outsourcing Playbook
Rewriting the Outsourcing Playbook

Macroeconomic headwinds, compressed regulatory pathways, and an influx of asset-light virtual innovators are leading to an evolution in outsourcing service delivery models.

AI-Designed Universal Coronavirus Vaccine Passes First Human Trial
AI-Designed Universal Coronavirus Vaccine Passes First Human Trial

A novel pan-sarbecovirus vaccine candidate developed by the University of Cambridge and DIOSynVax has demonstrated safety in a Phase I, needle-free clinical trial.

De-Risking the Scale-Up Pathway
De-Risking the Scale-Up Pathway

SPONSORED CONTENT: Pedro Fernandes Botas and Mark Macdonald from Codis break down how advanced spray drying capabilities, mathematical modeling, and commercial operations experience are helping sponsors navigate the modern formulation landscape.

Building a Modern Biotech Workforce
Building a Modern Biotech Workforce

As specialized modalities push classical manufacturing models to their limits, organizations must treat internal talent development with the same level of process excellence they apply to biological pipelines.

Regulatory

Featured
FDA Extends Review of AstraZeneca’s Camizestran
FDA Extends Review of AstraZeneca’s Camizestran

AstraZeneca’s camizestrant has faced a regulatory setback in the U.S., with the FDA extending its review, seeking clearer evidence that early intervention improves long-term outcomes for patients with advanced breast cancer.

First Targeted CSU Therapy for Children Gets Nod from European Commission
First Targeted CSU Therapy for Children Gets Nod from European Commission

The European Commission has approved dupilumab (Dupixent) as the first targeted therapy for chronic spontaneous urticaria (CSU) in children in the EU, broadening its use in type‑2‑driven inflammatory diseases.

Roche's pMN Therapy Meets Primary Endpoint in Phase III Trial
Roche's pMN Therapy Meets Primary Endpoint in Phase III Trial

The company has revealed that its humanized, glycoengineered Type II anti-CD20 mAb has achieved superior complete remission rates versus tacrolimus in the MAJESTY study.

Rilzabrutinib Gains Regulatory Nods in the U.S. and Japan
Rilzabrutinib Gains Regulatory Nods in the U.S. and Japan

The U.S. FDA has granted breakthrough therapy designation and Japan’s MHLW has designated orphan drug status to Sanofi’s BTK inhibitor, rilzabrutinib (Wayrilz), as a treatment for wAIHA.

Upcoming Events

Featured
DIA Global Annual Meeting 2026

The DIA Global Annual Meeting is where life sciences professionals from industry, regulatory agencies, patients, and academia come together to drive breakthroughs in healthcare — advancing science, policy, and patient outcomes worldwide.

Fierce BIO Preview 2026

Join industry leaders for a fast-paced, insider look at the trends, challenges, and opportunities everyone will be talking about on the ground.